Literature DB >> 30357936

Genotype-phenotype relations for the Parkinson's disease genes SNCA, LRRK2, VPS35: MDSGene systematic review.

Joanne Trinh1, Florentine M J Zeldenrust2, Jana Huang2, Meike Kasten1,3, Susen Schaake1, Sonja Petkovic1, Harutyun Madoev1, Anne Grünewald1,4, Shahad Almuammar2, Inke R König5, Christina M Lill1, Katja Lohmann1, Christine Klein1, Connie Marras2.   

Abstract

This comprehensive MDSGene review is devoted to the three autosomal-dominant PD forms: PARK-SNCA, PARK-LRRK2, and PARK-VPS35. It follows MDSGene's standardized data extraction protocol, screened a total of 2,972 citations, and is based on fully curated phenotypic and genotypic data on 937 patients with dominantly inherited PD attributed to 44 different mutations in SNCA, LRRK2, or VPS35. All of these data are also available in an easily searchable online database (www.mdsgene.org), which additionally provides descriptive summary statistics on phenotypic and genetic data. Despite the high degree of missingness of phenotypic features and unsystematic reporting of genotype data in the original literature, the present review recapitulates many of the previously described findings including later onset of disease (median age at onset: ∼49 years) compared to recessive forms of PD of an overall excellent treatment response. Our systematic review validates previous reports showing that SNCA mutation carriers have a younger age at onset compared to LRRK2 and VPS35 (P < 0.001). SNCA mutation carriers often have additional psychiatric symptoms, and although not exclusive to only LRRK2 or VPS35 mutation carriers, LRRK2 mutation carriers have a typical form of PD, and, lastly, VPS35 mutation carriers have good response to l-dopa.
© 2018 International Parkinson and Movement Disorder Society. © 2018 International Parkinson and Movement Disorder Society.

Entities:  

Keywords:  zzm321990LRRK2; zzm321990SNCA; zzm321990VPS35; Parkinson's disease; genetics

Mesh:

Substances:

Year:  2018        PMID: 30357936     DOI: 10.1002/mds.27527

Source DB:  PubMed          Journal:  Mov Disord        ISSN: 0885-3185            Impact factor:   10.338


  34 in total

Review 1.  LRRK2 in Parkinson disease: challenges of clinical trials.

Authors:  Eduardo Tolosa; Miquel Vila; Christine Klein; Olivier Rascol
Journal:  Nat Rev Neurol       Date:  2020-01-24       Impact factor: 42.937

2.  Using global team science to identify genetic parkinson's disease worldwide.

Authors:  Eva-Juliane Vollstedt; Meike Kasten; Christine Klein
Journal:  Ann Neurol       Date:  2019-06-26       Impact factor: 10.422

3.  Is serotonin pathology a good biomarker in vivo for early Parkinson's disease?

Authors:  Celia Painous; Andres Perissinotti; Maria J Martí
Journal:  Ann Transl Med       Date:  2019-12

Review 4.  Genetics of synucleins in neurodegenerative diseases.

Authors:  José Brás; Elizabeth Gibbons; Rita Guerreiro
Journal:  Acta Neuropathol       Date:  2020-08-01       Impact factor: 17.088

Review 5.  Neuropathology and pathogenesis of extrapyramidal movement disorders: a critical update-I. Hypokinetic-rigid movement disorders.

Authors:  Kurt A Jellinger
Journal:  J Neural Transm (Vienna)       Date:  2019-06-18       Impact factor: 3.575

Review 6.  Deep Brain Stimulation in Patients With Mutations in Parkinson's Disease-Related Genes: A Systematic Review.

Authors:  Lais Machado de Oliveira; Egberto Reis Barbosa; Camila Catherine Aquino; Renato Puppi Munhoz; Alfonso Fasano; Rubens Gisbert Cury
Journal:  Mov Disord Clin Pract       Date:  2019-06-19

7.  Nonsteroidal Anti-inflammatory Use and LRRK2 Parkinson's Disease Penetrance.

Authors:  Marta San Luciano; Caroline M Tanner; Cheryl Meng; Connie Marras; Samuel M Goldman; Anthony E Lang; Eduardo Tolosa; Birgitt Schüle; J William Langston; Alexis Brice; Jean-Christophe Corvol; Stefano Goldwurm; Christine Klein; Simone Brockman; Daniela Berg; Kathrin Brockmann; Joachim J Ferreira; Meriem Tazir; George D Mellick; Carolyn M Sue; Kazuko Hasegawa; Eng King Tan; Susan Bressman; Rachel Saunders-Pullman
Journal:  Mov Disord       Date:  2020-07-14       Impact factor: 10.338

Review 8.  Genetic Testing for Parkinson Disease: Are We Ready?

Authors:  Lola Cook; Jeanine Schulze; Catherine Kopil; Tara Hastings; Anna Naito; Joanne Wojcieszek; Katelyn Payne; Roy N Alcalay; Christine Klein; Rachel Saunders-Pullman; Tatyana Simuni; Tatiana Foroud
Journal:  Neurol Clin Pract       Date:  2021-02

9.  Therapies for Genetic Forms of Parkinson's Disease: Systematic Literature Review.

Authors:  Laura Over; Norbert Brüggemann; Katja Lohmann
Journal:  J Neuromuscul Dis       Date:  2021

10.  Serum lipid profile among sporadic and familial forms of Parkinson's disease.

Authors:  Daniel Macías-García; María Teresa Periñán; Laura Muñoz-Delgado; María Valle Jimenez-Jaraba; Miguel Ángel Labrador-Espinosa; Silvia Jesús; Dolores Buiza-Rueda; Carlota Méndez-Del Barrio; Astrid Adarmes-Gómez; Pilar Gómez-Garre; Pablo Mir
Journal:  NPJ Parkinsons Dis       Date:  2021-07-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.